JOHN BRENNAN: Open Payments
NPI 1336123173 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,051 in 159 payments from 16 companies in 2025. Trend: 2023 $2,257 · 2024 $2,518 · 2025 $3,051
Food & beverage: $3,051
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $456 |
| Otsuka America Pharmaceutical, Inc. | 17 | $397 |
| Vanda Pharmaceuticals Inc. | 18 | $396 |
| ABBVIE INC. | 22 | $336 |
| Bausch Health US, LLC | 17 | $271 |
| Lundbeck LLC | 13 | $258 |
| Tris Pharma Inc | 11 | $255 |
| Alkermes, Inc. | 8 | $195 |
| Almatica Pharma LLC | 10 | $180 |
| Noven Therapeutics, LLC | 4 | $66 |
Products named: REXULTI, CAPLYTA, FANAPT, VRAYLAR, Dyanavel XR, ARISTADA, LOREEV XR, WELLBUTRIN.
Industry payments across TX — which companies pay providers there.
